We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Pamela D. Butler is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1994 — 1995 |
Butler, Pamela D |
R03Activity Code Description:
To provide research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies which are generally for preliminary short-term projects and are non-renewable. |
Clinical Studies of Neurotensin in Schizophrenia @ New York State Psychiatric Institute
Neurotensin (NT) has been termed an "endogenous neuroleptic" because of its behavioral and biochemical similarities to antipsychotic drugs in preclinical studies and because of its known interactions with brain dopamine (DA) neurons. This is a clinical proposal that will explore alterations in NT concentrations in patients with schizophrenia. The proposed studies will test the following hypotheses: that cerebrospinal fluid (CSF) concentrations of NT and the related peptide neuromedin N (NMN) will be decreased in drug-free patients with schizophrenia compared to normal controls; that treatment with a typical and an atypical antipsychotic drug will both increase CSF NT and NMN concentrations from pre-drug levels in patients with schizophrenia; that both treatment- induced alterations in NT and/or NMN concentrations will be related to treatment response; and that NT and/or NMN concentrations will be related to peripheral indices of DA function. These hypotheses will be tested by the following specific aims: 1) determine whether the previous finding of decreased CSF NT concentrations in drug-free patients with schizophrenia compared to age and sex-matched normal controls is a reliable and reproducible finding and whether there is also decreased CSF NMN in these patients; 2) examine whether treatment with haloperidol and clozapine increases CSF concentrations of NT or NMN from pre-drug levels in patients with schizophrenia; 3) determine whether changes in CSF NT or NMN concentrations are related to treatment response in patients receiving haloperidol or clozapine; and 4) examine whether CSF NT or NMN concentrations are related to peripheral indices of DA function in patients with schizophrenia or are related to plasma drug concentrations. The potential impact of these studies is that they will yield important information about the role of NT and NMN in schizophrenia and their response to two classes of antipsychotic drugs, which may be efficacious in different populations of patients with schizophrenia. A greater understanding of the role of NT and NMN in antipsychotic drug response may be useful in the development of lipophilic NT agonists for treatment of schizophrenia.
|
0.939 |
| 2004 — 2008 |
Butler, Pamela D |
R01Activity Code Description:
To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Visual Processing in Schizophrenia @ Nathan S. Kline Institute For Psych Res
DESCRIPTION (provided by applicant): Sensory processing deficits constitute a central feature of schizophrenia. This project will investigate the basis of visual pathway dysfunction in schizophrenia using complementary neurophysiological and psychophysical measures and MRI. Neurocognitive, including visual processing, deficits have been linked to functional outcome in schizophrenia. A secondary goal of this project is to examine the relationship between visual pathway dysfunction and social/global outcome deficits in schizophrenia. Human visual processing is conducted through parallel magnocellular and parvocellular pathways, which extend mainly into dorsal stream (parietal lobe) and ventral stream (temporal lobe) regions, respectively. Dorsal stream dysfunction has been well documented in schizophrenia. Increasing evidence suggests dorsal stream deficits are due to lower level magnocellular dysfunction. Understanding integrity of visual pathways is crucial to understanding higher level visual dysfunction in schizophrenia. A unique feature of this application is the use of visual evoked potentials (VEP) to evaluate integrity of visual pathways. High density VEP recordings will provide information not only about magnocellular versus parvocellular dysfunction, but also about localization of deficits. MRI studies will evaluate white matter integrity in lower level as well as dorsal and ventral visual stream areas. These combined techniques will provide important information regarding localization of the deficit. VEP and psychophysical studies will be highly integrated with studies of social/global outcome. The specific aims are: 1) to further characterize magnocellular versus parvocellular visual pathway dysfunction in schizophrenia; 2) to explore relationships between magnocellular visual pathway dysfunction and social/global functioning deficits in patients with schizophrenia; and 3) to examine structural correlates of visual processing dysfunction in patients with schizophrenia.
|
0.988 |